whitepaper

Application note: High-throughput IgG quantitation platform for clone screening during drug discovery and development

Posted: 14 July 2021 | | No comments yet

Every manufacturing process for potential biologics begins with cell line development, whether it’s for clinical trials or a market launch.

The accurate and reliable measurement of mAb (e.g., IgG) titer is essential in the development and subsequent manufacture to ensure optimal cell culture performance for the production of all biologics. The ability to reliably monitor protein titer in real time throughout a bioprocess allows operators to rapidly adjust the process conditions for maximum protein output while minimizing process time.












    To read this application note in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Molecular Devices

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Send this to a friend